Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 20.3171
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 10830872580.0
- FreeCF/Share 1.0821
- PFCF 45.0879
- PE 67.8816
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.
Read More
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy– Hagens Berman
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. Sookdeo v.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options
Read More
Hims & Hers Health, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - HIMS
Published: July 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025.
Read More
Hims & Hers to offer generic semaglutide in Canada starting in 2026
Published: July 09, 2025 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS) announced plans to expand its digital health and weight loss services to Canada in 2026, coinciding with the first global availability of generic semaglutide. Beginning in January 2026, Canada will become the first country to offer generic versions of semaglutide, a GLP-1 receptor agonist widely used for weight management under brand names such as Wegovy and Ozempic.
Read More
Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: July 09, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 9, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) have opportunity to lead the securities fraud class action lawsuit.
Read More
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 09, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 9, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
Read More
Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS
Published: July 09, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 9, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.
Read More
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: July 09, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , July 9, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v.
Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Published: July 09, 2025 by: CNBC
Sentiment: Positive
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Read More
Shareholders of Hims & Hers Health, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – HIMS
Published: July 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit.
Read More
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Hims & Hers Health Inc. to Contact Law Firm
Published: July 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 8, 2025 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Hims & Hers Health, Inc. (NYSE: HIMS) Shareholders should email [email protected] The investigation concerns a recent announcement about the Novo Nordisk collaboration. On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform.
Read More
HIMS Investors Have the Opportunity to Lead the Hims & Hers Health Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Published: July 08, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 8, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, …
Read More
Hims & Hers Health: Unlocking A $6 Billion Future
Published: July 08, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers grew Q1 2025 revenue by 111% to $586 million, with adjusted EBITDA nearly tripling to $91 million. Nearly 60% of the 2.4 million subscribers now use personalized treatments, boosting retention and average revenue per user to $84. Despite the Novo Nordisk split, the diversified GLP-1 and weight loss portfolio targets $725 million in 2025 specialty revenue.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
Published: July 07, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HIMS
Published: July 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 07, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers' top executives with violations of the Securities …
Read More
Health Meets Lifestyle: How Hims & Hers Is Reshaping Everyday Wellness
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS is transforming digital wellness with personalized care, over 30 million telehealth consultations, and a Gen Z-aligned platform.
Read More
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: July 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, July 07, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).
Read More
HIMS & HERS HEALTH, INC. (NYSE: HIMS) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Hims & Hers Health, Inc. Investors of Upcoming Deadline
Published: July 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit?
Read More
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Published: July 07, 2025 by: Benzinga
Sentiment: Negative
Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company's stock has plummeted approximately 18% over the past month, reflecting recent challenges.
Read More
HIMS Investors with Losses in Excess of $100K Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
Published: July 07, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025 lead plaintiff deadline. So what: If you purchased Hims common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy– Hagens Berman
Published: July 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. Sookdeo v.
Read More
HIMS SHAREHOLDERS: The Hims & Hers Health, Inc. August 25 Class Action Deadline is Approaching -- Contact BFA Law if You Suffered Losses (NYSE:HIMS)
Published: July 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.
Read More
Robbins LLP Urges HIMS Stockholders with Large Losses to Contact the Firm for Information About the Class Action Pending Against Hims & Hers Health, Inc.
Published: July 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025. Hims operates a telehealth platform that connects consumers to licensed healthcare professionals.
Read More
Hims & Hers Enhances Healthcare Through AI-Driven Personalization
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS taps AI and $870 million in funding to deliver smarter, more personalized healthcare through tech-driven innovation.
Read More
Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: July 03, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , July 3, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - HIMS
Published: July 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as certain of Hims & Hers' top executives with violations of the Securities Exchange Act of …
Read More
Class Action Filed Against Hims & Hers Health, Inc. (HIMS) - August 25, 2025 Deadline to Join - Contact The Gross Law Firm
Published: July 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Class Action Filed Against Hims & Hers Health, Inc. (HIMS) - August 25, 2025 Deadline to Join - Contact The Gross Law Firm
Published: July 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637